Ausgabe 4/2007
Inhalt (15 Artikel)
Evaluation of ABT-751 against childhood cancer models in vivo
Christopher L. Morton, Edward G. Favours, Kimberly S. Mercer, Claire R. Boltz, Jeri Carol Crumpton, Chandra Tucker, Catherine A. Billups, Peter J. Houghton
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro
Elin Lindhagen, Linda Rickardson, Gary Elliott, Lorenzo Leoni, Peter Nygren, Rolf Larsson, Anna Åleskog
Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines
Denise K. Walters, Roman Muff, Bettina Langsam, Philipp Gruber, Walter Born, Bruno Fuchs
A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance
Gene L. Bidwell III, Aisha N. Davis, Izabela Fokt, Waldemar Priebe, Drazen Raucher
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
J. H. Beumer, R. C. Garner, M. B. Cohen, S. Galbraith, G. F. Duncan, T. Griffin, J. H. Beijnen, J. H. M. Schellens
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
Martee L. Hensley, Don Dizon, Felicia Derosa, Ennapadam Venkatraman, Paul Sabbatini, Dennis S. Chi, Jakob Dupont, A. Dimitrios Colevas, David Spriggs, Carol Aghajanian
Pro-apoptotic activity of imidazole derivatives mediated by up-regulation of Bax and activation of CAD in Ehrlich Ascites Tumor cells
C. Anil Kumar, Shankar Jayarama, Basappa, Bharathi P. Salimath, Kanchugarakoppal S. Rangappa
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
Angela M Davies, Cheryl Ho, Paul J Hesketh, Laurel A Beckett, Primo N Lara Jr, Derick HM Lau, David R Gandara
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes
Quincy S. C. Chu, Bahram Forouzesh, Samira Syed, Monica Mita, Garry Schwartz, Joshua Cooper, Janet Curtright, Eric K. Rowinsky
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas
Quincy S. C. Chu, Bahram Forouzesh, Samira Syed, Monica Mita, Garry Schwartz, Joshua Copper, Janet Curtright, Eric K. Rowinsky
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
Nancy U. Lin, Leroy M. Parker, Steven E. Come, Harold J. Burstein, Margaret Haldoupis, Nicole Ryabin, Rebecca Gelman, Eric P. Winer, Lawrence N. Shulman
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study
Koji Takeda, Nobuhide Takifuji, Shunichi Negoro, Kiyoyuki Furuse, Shinichiro Nakamura, Yoshiki Takada, Takanobu Hoso, Shinichi Hayasaka, Takashi Nakano, Jun Araki, Hiroshi Senba, Fumiyuki Iwami, Yasufumi Yamaji, Masahiro Fukuoka, Harumichi Ikegami
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers
T. Ciuleanu, M. Diculescu, N. M. Hoepffner, J. Trojan, V. Sailer, M. Zalupski, T. Herrmann, A. Roth, J. Chick, K. Brock, D. Albert, P. A. Philip
Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway
Pavel Krejci, Katerina Pejchalova, William R. Wilcox
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro soft-agar cloning experiments
Axel-Rainer Hanauske, Olaf Oberschmidt, Hartmut Hanauske-Abel, Michael M. Lahn, Ulrike Eismann